Keyphrases
Anticoagulation
50%
Apixaban
100%
Arterial Thromboembolism
25%
Bleeding
50%
Clinical Outcomes
100%
Clinically Significant
50%
COVID-19
75%
COVID-19 Hospitalization
100%
Decline Rate
25%
Delta Variant
25%
Disease Severity
25%
Drug Treatment
25%
Event Rate
25%
Extended Thromboprophylaxis
25%
Hispanic
25%
Hospital Discharge
25%
Hospitalization
50%
In(III)
25%
Increased Incidence
25%
Lost to Follow-up
25%
Major Bleeding
50%
Medical Prevention
25%
Non-majors
50%
Omicron Variant
25%
Placebo
100%
Placebo Groups
25%
Primary Safety
25%
Prospective Randomized Trial
25%
Randomized Placebo-controlled Trial
25%
Risk Prediction Score
25%
SARS-CoV-2 Vaccine
25%
Severity Score
25%
Thromboembolic Complications
25%
Thromboembolism
50%
Thromboprophylaxis
100%
Twice Daily
25%
United States
25%
US Hospitals
25%
Venous Thromboembolism
25%
Venous Thromboembolism Risk
25%
World Health Organization
25%
Medicine and Dentistry
Anticoagulation
33%
Apixaban
66%
Arterial Thromboembolism
16%
Bleeding
33%
Contraindication
16%
Controlled Clinical Trial
16%
COVID-19
100%
COVID-19 Vaccine
16%
Disease Severity
16%
Drug Therapy
16%
Major Bleeding
33%
Omicron Coronavirus Variant
16%
Placebo
100%
Thromboembolism
50%
Thromboprophylaxis
100%
Venous Thromboembolism
33%
Pharmacology, Toxicology and Pharmaceutical Science
Apixaban
66%
Arterial Thromboembolism
16%
Bleeding
66%
Controlled Clinical Trial
16%
COVID-19 Vaccine
16%
Disease Severity
16%
Pharmacotherapy
16%
Placebo
100%
Thromboembolism
50%
Venous Thromboembolism
33%